Journal Summary: Vitiligo Journal Summary: Vitiligo
Journal Summaries provide a quick review of recent journal articles with current or near-term clinical significance. Catch up on key research on vitiligo from the past year.Medscape Dermatology (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 6, 2023 Category: Dermatology Tags: Dermatology Commentary Source Type: news
Utilization of Topical Ruxolitinib in Dermatology Utilization of Topical Ruxolitinib in Dermatology
This review summarizes the use of topical ruxolitinib, a JAK inhibitor, in various dermatological conditions including vitiligo, alopecia areata, atopic dermatitis, psoriasis, and more.Skin Therapy Letter (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 4, 2023 Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news
Topical Ruxolitinib for Vitiligo: First-Year Experiences Topical Ruxolitinib for Vitiligo: First-Year Experiences
Some dermatologists recommend combining the treatment with phototherapy and advise that results can take many months to see.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 23, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
Lichen Sclerosus: Study Highlights Diagnostic Challenge Lichen Sclerosus: Study Highlights Diagnostic Challenge
The aim of the study was to characterize differences in LS and vitiligo based on history, physical exam, and demographic findings at the time of the initial clinic visit.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 9, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
Ruxolitinib Response in Teens, Adults With Vitiligo Compared Ruxolitinib Response in Teens, Adults With Vitiligo Compared
Pooled data from the phase 3 TRuE-V1 and TRuE-V2 studies were used to evaluate responses in a subset of adolescents treated with the topical JAK inhibitor for vitiligo.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 25, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
Camp for Kids With Skin Disorders Marks 30th Anniversary Camp for Kids With Skin Disorders Marks 30th Anniversary
The camp, sponsored by the American Academy of Dermatology, accepts youth with conditions ranging from eczema and psoriasis to vitiligo, alopecia, epidermolysis bullosa, and ichthyosis.MDedge News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 25, 2023 Category: Allergy & Immunology Tags: Dermatology News Source Type: news
Incidence Rate of Diagnosed Vitiligo 22.6 per 100,000 Person-Years
MONDAY, July 24, 2023 -- Vitiligo diagnosis is more common in older adults and in Hispanic/Latino and Asian American patients, according to a study published online July 19 in JAMA Dermatology.
Nicole Mastacouris, from the Donald and Barbara Zucker... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 24, 2023 Category: Pharmaceuticals Source Type: news
Study Examines Burden of Vitiligo in the US Study Examines Burden of Vitiligo in the US
Prior population-based prevalence estimates of vitiligo vary because of differences in study design and data collection methods, the authors note.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - July 19, 2023 Category: Internal Medicine Tags: Dermatology News Source Type: news
Approval for £1,000 cream to treat skin condition vitiligo that affects fashion model Winnie Harlow
Regulators have approved the first effective treatment for vitiligo, which causes white areas to develop on the body. The condition affects Victoria's Secret lingerie model Winnie Harlow (pictured). (Source: the Mail online | Health)
Source: the Mail online | Health - July 15, 2023 Category: Consumer Health News Source Type: news
The Nuances of Treating Vitiligo in People of Color
There are challenges in treating vitiligo in people of color. An expert discusses these and newer therapies on the horizon. (Source: WebMD Health)
Source: WebMD Health - May 29, 2023 Category: Consumer Health News Source Type: news
Treating Vitiligo: Build a Care Team You Trust
Here’s what to look for as you assemble your vitiligo health care team. (Source: WebMD Health)
Source: WebMD Health - May 26, 2023 Category: Consumer Health News Source Type: news
Changing the lives of patients with alopecia and vitiligo
Meet Dr. Brett King, the Yale dermatologist who advocated for the first FDA-approved treatments for these two life-altering conditions. (Source: Yale Science and Health News)
Source: Yale Science and Health News - May 22, 2023 Category: Universities & Medical Training Source Type: news
Cochrane Lifetime and Emeritus Members
Cochrane is proud to announce new lifetime and emeritus memberships,recognizing the extraordinary contributions of individuals who have made an exceptional, long-standing contribution to Cochrane ’s work and leadership.Cochrane ' s strength is in its collaborative, global community. Over the last 30 years, our members and supporters from more than 130 countries have worked together to produce credible, accessible health information and help inform health decision-making. Though we are spread out across the globe, our shared passion for health evidence unites us.Cochrane ’s Membership schemehelps reward everyone who hel...
Source: Cochrane News and Events - May 3, 2023 Category: Information Technology Authors: Muriah Umoquit Source Type: news
Ruxolitinib for Vitiligo Approved for Marketing in EU Ruxolitinib for Vitiligo Approved for Marketing in EU
Last year in the United States, the topical JAK inhibitor became the first repigmentation treatment approved by the FDA for nonsegmental vitiligo, the most common form of the disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 21, 2023 Category: Consumer Health News Tags: Dermatology News Source Type: news
AAD: Long-Term Improvement Seen With Ruxolitinib in Vitiligo
TUESDAY, March 28, 2023 -- For patients with nonsegmental vitiligo, continued improvement in seen during a long-term extension of ruxolitinib treatment, according to study presented at the annual meeting of the American Academy of Dermatology, held... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 28, 2023 Category: Pharmaceuticals Source Type: news
